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Isoprostane, an “Intermediate Phenotype”
for Oxidative Stress
Heritability, Risk Trait Associations, and
the Influence of Chromogranin B Polymorphism
Fangwen Rao, MD, Kuixing Zhang, MD, PHD, Srikrishna Khandrika, PHD, Manjula Mahata, PHD,
Maple M. Fung, MD, Michael G. Ziegler, MD, Brinda K. Rana, PHD, Daniel T. O’Connor, MD
San Diego, California
Objectives The purpose of this study is to understand whether isoprostane, a biomarker of oxidative stress, is subject to
heritable control; whether it shares heritability with other cardiometabolic risk traits; and finally whether genetic
variation at a specific candidate locus contributes to isoprostane variability.
Background Isoprostane marks oxidative stress, and elevated isoprostane excretion might be involved in cardiovascular tar-
get organ damage. Here we used the classical twin pair method to probe the role of heredity in generating the
isoprostane trait.
Methods Trait heritability (h2) and shared genetic determination among traits (pleiotropy, genetic covariance, G) were
estimated by variance components in twin pairs. Because the isoprostane and Chromogranin B (CHGB) traits
shared G, we examined the CHGB locus for effects on the traits.
Results Urinary isoprostane excretion was substantially heritable (h2  65.8  4.3%), and the isoprostane trait aggre-
gated with multiple traits (CHGB, catecholamines, autonomic/baroreceptor, and renal function), including sev-
eral features of the metabolic syndrome (body mass index, insulin resistance, dyslipidemia). Isoprostane excre-
tion also aggregated with systemic hypertension. Twin studies demonstrated genetic covariance (pleiotropy) for
the isoprostane and CHGB traits (G  0.27), and therefore we investigated the CHGB locus for trait effects. A
common variant in the 3=-UTR of CHGB (C84A) associated with plasma CHGB as well as isoprostane excretion.
The C84A disrupted an A/U-rich messenger ribonucleic acid stability element, and in transfected luciferase/
3=-UTR plasmids, the C84 and 84A alleles differed markedly in reporter expression in chromaffin and neuro-
blastoma cells, whereas site-directed mutagenesis confirmed the importance of this variant within the context of
the A/U-rich motif.
Conclusions Isoprostane excretion is substantially heritable and shares joint genetic determination with CHGB as well as mul-
tiple features of the metabolic syndrome. A common polymorphism in the 3=-UTR (C84A) of CHGB, which dis-
rupts an A/U-rich messenger ribonucleic acid stability element, associates with not only CHGB secretion but also
excretion of isoprostane. We propose a chain of events whereby CHGB genetic variation results in oxidative
stress, with isoprostane formation. The results suggest novel links among the catecholaminergic system, oxida-
tive pathways, and systemic hypertension. (J Am Coll Cardiol 2010;56:1338–50) © 2010 by the American
College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2010.03.092i
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exidative stress is characterized by an imbalance between
ncreased exposure to free radicals and antioxidant defenses.
xidative damage of any of the biomolecules can theoreti-
ally contribute to disease development. Indeed, an increas-
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echanisms of multiple acute and chronic human diseases
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October 12, 2010:1338–50 Isoprostane and Heredityhe pathophysiology of essential hypertension (3,4) and
ardiovascular diseases (5–7), although the origin and sig-
ificance of such oxidative damage is still incompletely
nderstood. Inflammation might contribute to or result
rom tissue injury after oxidative stresses, inflammatory
ediators generated by pathogens, genetic factors, or de-
letion of endogenous anti-inflammatory mediators. The
nflammatory response might be accompanied by release of
xygen radicals (8,9) that deplete endogenous nitrovasodi-
ators, causing vasoconstriction (10,11), thereby raising BP.
Isoprostanes are chemically stable end-products of lipid
eroxidation derived from arachidonic acid (12). A series of
soprostanes might be generated, but most interest has
ocused on F2-isoprostanes, particularly on 8-iso-PGF2
also known as 8-epi-PGF2 or 15-isoprostane F2t) be-
ause of its biological activity (13). As products of lipid
eroxidation, F2-isoprostanes are considered to be reliable
arkers of enhanced systemic oxidative stress in vivo
14,15). In the human circulation, isoprostanes are present
ainly in their ester forms, whereas only hydrolyzed iso-
rostanes are excreted in the urine. The presence of detect-
ble concentrations of isoprostanes in biological fluids im-
lies continuing lipid peroxidation, despite the presence of a
omplex network of antioxidant defenses. As well as being
he best available marker of oxidative stress, some isopros-
anes have biological activities that might be relevant to the
athophysiology of disease (16). The 8-iso-PGF2 is a
otent vasoconstrictor in the rat, and its action has been
hown to be mediated at least in part via interaction with a
XA2/PGH2 receptor (13). Isoprostanes have also been
hown to enhance vasoconstriction in hypercholesterolemia
oth in vitro (13,17) and in vivo (18). Thus, 8-iso-PGF2
s not only a marker of but also a participant in the
athophysiology of disease.
Urinary and/or plasma isoprostanes are increased in and
ssociated with several features of the metabolic syndrome,
ncluding hypercholesterolemia (19,20), hypertension (21),
nd diabetes mellitus (22). In addition to their association
ith cardiovascular risk factors, isoprostanes are also in-
reased in patients with established vascular disease (23).
amilial correlations indicate that hypertension is, at least in
art, a genetically determined condition (24) and likely
urther enhanced by environmental factors. Here we hy-
othesized that 8-iso-PGF2 is also subject to genetic
etermination and tested this hypothesis by evaluating the
eritability (h2) of the trait, where h2 is the fraction of trait
ariance accounted for by genetic variance (h2  VG/VP).
e estimated h2 with the classical twin method (25), with
oth monozygotic and dizygotic twin pair correlations. We
valuated physiological traits and biochemical traits for
hared genetic determination, with the genetic covariance
26) in twin pairs. Because blood pressure (BP) is adrener-
ically mediated, we coupled estimates of twin h2 with
llelic variation at chromogranin B (CHGB), which was first
escribed in 1985 (27,28) as a major catecholamine storage wesicle core protein and seems to
lay a necessary role in the bio-
enesis of catecholamine secre-
ory vesicles (29,30).
ethods
win and sibling pairs. Twin
ecruitment proceeded by access
o a population birth record-
ased twin registry (31) as well as
y newspaper advertisement, as
escribed by us (32). We re-
ruited 519 individuals from 194
win pairs and 131 additional
iblings of twins and other sib-
ing pairs. From the 194 complete twin pairs, there were 130
onozygotic pairs (25 M/M and 105 F/F pairs) and 64 DZ
airs (13 M/M, 39 F/F, and 12 M/F pairs). Twin zygosity
ssignment was based on self-identification, with further
onfirmation by the presence or absence of heterozygosity at
he (TCAT)n microsatellite (32) (unshared alleles necessar-
ly indicating dizygotic status). The 519 subjects were all
hite (European ancestry); ethnicity was established by
elf-identification as well as by identification for both
arents and all 4 grandparents. Twin ages were 14 to 81
ears. Four hundred sixty-three individuals were normoten-
ive, and 56 were hypertensive (41 treated with 1 to 2
ntihypertensive medications; 15 untreated); BP status
high vs. normal) was defined by history (medical record or
elf-report), presence or absence of antihypertensive medica-
ions, and measurement of seated BP by arm cuff (hyperten-
ion: 140 mm Hg systolic BP and/or 90 mm Hg diastolic
P). Self-reported family history of hypertension (in a first-
egree relative before the age of 60 years) was determined as
escribed (33). Although self-reported family history of hyper-
ension is generally accurate (34), in family studies with
scertainment of both probands and relatives (35), the speci-
city of a positive family history of hypertension is high
90%) (i.e., few false positives); however, the sensitivity is
ariable (i.e., false negatives might occur). None of the subjects
ad a history of renal failure, and serum creatinine concentra-
ions were 1.5 mg/dl. Definitions of subject characteristics
re according to previous reports from our laboratory. Subjects
ere volunteers from southern California, and each subject
ave informed, written consent; the protocol was approved by
he University of California at San Diego (UCSD) Human
esearch Protection Program.
hysiological phenotyping in vivo. Subjects were studied
efore genotyping. Wild-type and variant subjects were
tudied during the same time interval. Brachial arterial cuff
P (in mm Hg) and heart rate (in beats/min) (n  519)
ere obtained in seated subjects with a DynaPulse device
PulseMetric, Vista, California), as previously described and
alidated. Triplicate determinations of BP and heart rate
Abbreviations
and Acronyms
BP  blood pressure
CHGB  chromogranin B
h2  heritability
HOMA  HOmeostatic
Model Assessment, insulin
resistance
LD  linkage disequilibrium
SNP  single nucleotide
polymorphism
SOLAR  Sequential
Oligogenic Linkage Analysis
Routinesere made, until each value was within 10% of the mean
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Isoprostane and Heredity October 12, 2010:1338–50alue. To probe autonomic control of the circulation in twin
airs, BP and heart rate were recorded continuously and
oninvasively for 5 min in seated, resting subjects with a
adial artery applanation device as well as thoracic electro-
ardiography electrodes and dedicated sensor hardware
Colin Pilot, Colin Instruments, San Antonio, Texas) and
oftware (ATLAS, WR Medical Electronics, Stillwater,
innesota; and Autonomic Nervous System, Tonometric
ata Analysis [ANS-TDA], Colin Instruments). Barore-
eptor coupling and baroreceptor slope were quantified as
reviously described (36).
ingle nucleotide polymorphisms at CHGB. DEOXYRI-
ONUCLEIC ACID. Genomic deoxyribonucleic acid (DNA)
as prepared from leukocytes in ethylenediaminetetraacetic
cid–anticoagulated blood, with PureGene extraction kits
Gentra Biosystems, Minneapolis, Minnesota).
INGLE NUCLEOTIDE POLYMORPHISM ASSAYS. Genotypes
t CHGB (30) in twin samples were scored on amplified
NA by extension-based methods: mass spectrometry
Sequenom, La Jolla, California), or pyrosequencing
Biotage, Uppsala, Sweden). The CHGB 3=-UTR variant
84A (rs2821) was in Hardy Weinberg Equilibrium
chi-square  4.09, p  0.152), with allele frequencies of
 60.5%/A  39.5% in subjects of European ancestry.
he position of CHGB 3=-UTR C/A variant rs2821 can be
escribed either in the 3=-UTR (C84A, numbered in base
airs [bp] downstream of the translation termination codon)
r in the gene (C13612A, numbered in bp downstream
rom the cap [transcription initiation] site).
haracterization of CHGB genetic variation in cella.
YMPATHOCHROMAFFIN CELL CULTURE. Rat pheochro-
ocytoma (chromaffin) PC12 cells were grown in Dulbec-
o’s modified Eagle/high-glucose medium supplemented
ith 5% heat-inactivated fetal bovine serum, 10% heat-
nactivated horse serum (Gemini Bio-products, Woodland,
alifornia), 100 U/ml penicillin G and 100 mg/ml strepto-
ycin (Invitrogen, Carlsbad, California) at 37°C, 6% car-
on dioxide, in either 10-cm plates or 12-well plates.
uman neuroblastoma SH-SY-5Y cells (ATCC) were
rown at 37°C with 5% carbon dioxide, in 10-cm plates in
0% Advanced MEM (Invitrogen) and Ham’s F12 (In-
itrogen) supplemented with 10% of heat-inactivated fetal
ovine serum, 100 U/ml penicillin and 100 mg/ml
treptomycin.
HGB 3=-UTR/LUCIFERASE REPORTER ACTIVITY ASSAYS.
he entire 308-bp CHGB 3=-UTR fragment was amplified
rom human genomic DNA with the following primers:
ense, 5=-GGTCTAGACTGTCATTGGAGCGGTGG-
=; antisense, 5=-GGTCTAGAGGTCTCAGGTGAA-
CTTT-3=. The XbaI (TCTAGA) restriction (ligation) site
s given in italics. The polymerase chain reaction product
nd pGL3-Promoter vector (with SV40 as promoter; Pro-
ega, Madison, Wisconsin) were each digested by restric-
ion enzyme XbaI separately, and the insert was then ligated
nto the vector with T4 DNA ligase. Correct insert orien- eation was confirmed by asymmetric double digestion with
estriction enzyme MfeI, which cuts once within the insert,
nd nearby in the vector at position 2103, within the SV40
A cassette. The primers for site-directed mutagenesis at
84A (on this template: A¡C) are as follows (mutation
n bold type): sense, 5=-CTGAAAGACACCATTTAT-
TACCCAAGGGCAGAAAGTA-3=; antisense, 5=-
ACTTTCTGCCCTTGGGTAGATAAATGGTGT-
TTTCAG-3=. Point mutations were confirmed by
ideoxy sequencing. The PC12 pheochromocytoma cells
ere transfected (at 50% to 60% confluence, 1 day after 1:4
plitting) with 1 g of firefly luciferase/CHGB 3=-UTR
eporter plasmid and 10 ng of the Renilla luciferase expression
lasmid pRL-CMV (Promega) (as an internal transfection
fficiency control) per well, by the liposomemethod (Superfect,
iagen, Valencia, California). Firefly and Renilla luciferase
ctivities in the cell lysates were measured 8 to 36 h after
ransfection, with the Dual Luciferase reporter assay system
Promega), and the results were expressed as the ratio of
refly/Renilla luciferase activity, as described previously (37).
ach experiment was repeated a minimum of 3 times. Lucif-
rase activity of C/A heterozygosity was estimated by a 1:1 mix
f the C or A allele plasmids.
iochemical phenotyping. ISOPROSTANE IN URINE. As an
ndex of systemic oxidative stress, we used the urinary
ontent of 8-iso-PGF2 (also known as 8-epi-PGF2 or
5-isoprostane F2t), a stable product of arachidonic acid
ormed on nonenzymatic oxidation. Untimed (“spot”) urine
amples were collected in the morning after at least a 3-h
ast, temporarily stored at 0°C for up to 1 h, and then
aintained at 80°C until analysis; urinary content of
-iso-PGF2 was indexed to creatinine concentration
measured by autoanalyzer) (Beckman-Coulter, Brea, Cal-
fornia) and expressed as pg/mmol creatinine. The content
f 8-iso-PGF2 determined with a commercially available
nzyme-linked immunoadsorbent assay (AMS Biotechnol-
gy [Europe], Ltd., Abingdon, United Kingdom). In brief,
fter sample dilution, 15-isoprostane F2t competes with the
ame antigen conjugated to horseradish peroxidase for
inding to a polyclonal antibody-coated microplate. Tetra-
ethylbenzidine substrate addition results in blue color
nversely proportional to the amount of 15-isoprostane F2t.
ddition of an acid stop solution causes a color change to
ellow, for which absorbance is read at 450 nm. The assay
ensitivity was 50 pg, with a dynamic range of 0.1 to 10
g/ml, and the average intra-assay coefficient of variation for
4 replicate samples was 1.72%. Cross-reactivities were
ndetectable (0.01%) for prostaglandins F2, E2, D2, or
rachidonic acid. The correlation between this method and
C/MS was r2 0.8 (r  0.89), as has been noted for
revious isoprostane immunoassays (38,39). Urinary con-
ent of 8-iso-PGF2 was indexed to creatinine concentra-
ion (measured by autoanalyzer) (Beckman-Coulter) and
xpressed as pg/mmol creatinine.
Cp
n
t
U
u
m
a
e
n
a
s
C
m
b
T
e
c
C
O
v
i
i
l
C
t
v
i
S
w
e
C
c
i
t
t
a
e
0
S
t
d
g
o
m
m
d
d
e
t
v
g
m
t
t
e
O
e
p
t
p
(
H
c
S
R
H
p
h
i
f
d
t
s
6
o
d
b
h
I
c
t
l
p
w
C
p
l
U
t
m
p
(
i
d
a
i
a
p
P
t
c
g
e
1341JACC Vol. 56, No. 16, 2010 Rao et al.
October 12, 2010:1338–50 Isoprostane and HeredityATECHOLAMINES. Blood samples for measurement of
lasma catecholamines were drawn into ethylenediami-
etetraacetic acid anticoagulant tubes and promptly chilled
o 0°C before separation of plasma and storage at 70°C.
rine samples were similarly stored. Batched, previously
nthawed samples were subjected to a sensitive radioenzy-
atic assay based on catechol-O-methylation (40). Intra-
ssay coefficients of variation were: norepinephrine 4%, and
pinephrine 13%. Inter-assay coefficients of variation were:
orepinephrine 10%, and epinephrine 16%. Urine catechol-
mine values were normalized to creatinine excretion in the
ame sample.
HROMOGRANIN B. The CHGB region-specific radioim-
unoassays (CHGB[439-451], CHGB[566-577]) were
ased on synthetic peptides, as previously described (41,42).
he [125I]-radiolabeling of each peptide was enabled by an
ndogenous or adventitious (terminal) Tyr residue. Poly-
lonal rabbit antisera were developed for the synthetic
HGB regions as described (43).
THER ASSAYS. Plasma lipids and apolipoproteins (224 indi-
iduals) were measured as previously described (44). Plasma
nsulin, leptin, and C-reactive protein were measured by
mmunoassay. Plasma glucose and plasma and urine electro-
ytes were measured by autoanalyzer (Beckman-Coulter).
alculations. Endogenous insulin sensitivity (or resis-
ance) was estimated from fasting plasma glucose and insulin
alues by HOMeostatic Assessment model (HOMA), an
ndex of insulin resistance (45).
tatistical analyses. Descriptive statistics (mean  SEM)
ere computed across all of the twins, with generalized
stimating equations (PROC GENMOD in SAS [SAS,
ary, North Carolina]), to take into account intra–twin-pair
orrelations (46). For isoprostane excretion values (pg/mmol),
nitial skewness  5.3  0.1, and kurtosis  50.0  0.2;
herefore, values were Log10-transformed for parametric sta-
istical analyses, including h2 by Sequential Oligogenic Link-
ge Analysis Routines (SOLAR) and generalized estimating
quations (post-Log10-transformation, skewness  1.3 
.3, and kurtosis  6.2  0.2). Trait-on-trait nonparametric
pearman correlations were performed with 1 individual per
win pair, to avoid false positive conclusions from nonindepen-
ent observations.
Estimates of h2 (h2  VG/VP, where VG is additive
enetic variance and VP is total phenotypic variance) were
btained with the variance-component methodology imple-
ented in the SOLAR package (47,48). This method
aximizes the likelihood of assuming a multivariate normal
istribution of phenotypes in twin pairs (monozygotic vs.
izygotic) with a mean dependent on a particular set of
xplanatory covariates. The null hypothesis (H0) of no h
2 is
ested by comparing the full model, which assumes genetic
ariation (VG), and a reduced model, which assumes no
enetic variation, with a likelihood ratio test. All h2 esti-
ates were adjusted for age and sex, because of the effects ofhese covariates on several traits (Table 1). iPleiotropy (genetic covariance for 2 correlated, heritable
raits; the cross-product of the trait heritabilities) (26) was
stimated as the parameter G in SOLAR (47). Sequential
ligogenic Linkage Analysis Routines was also used to
stimate the environmental covariance, as parameter E.
Haplotypes were inferred from common single nucleotide
olymorphisms (minor allele frequency10%) of CHGB by
he HAP algorithm (49), which can also generate a likely
hylogeny for each variant. Pair-wise linkage disequilibrium
LD) between common SNPs was quantified as r2*100, by
aploview (50).
Data were stored in Microsoft Access, and analyses were
onducted in SPSS (SPSS, Chicago, Illinois), SAS, or
OLAR.
esults
eritability of isoprostane excretion. Trait h2 (the pro-
ortion of trait variation accounted for by genetic variation;
2  VG/VP) was estimated from twin pair correlations and
s shown in Table 1, expressed as percentage (i.e., h2 scaled
rom 0% to 100%). Urinary isoprostane excretion h2 is also
isplayed graphically, within the context of other features of
he metabolic syndrome, in Figure 1. Heritability was
ignificant (p  5.48E-22) for isoprostane excretion, at
5.8  4.3% of trait variance. Table 1 lists h2 for a variety
f traits, including multiple features of the metabolic syn-
rome as well as a number of autonomic traits, both
iochemical (e.g., catecholamines) and physiological (e.g.,
eart rate variability).
soprostane trait correlations. Nonparametric (Spearman)
orrelations of urinary isoprostane excretion with other
raits are also shown in Table 1. Several phenotypes corre-
ated with urinary isoprostane excretion, both physical/
hysiological and biochemical. Prominent correlations
ere found for urinary catecholamine excretion, plasma
HGB439–451, glomerular filtration rate, and several com-
onents of the metabolic syndrome: C-reactive protein,
eptin, insulin, HOMA, and vascular compliance.
rinary isoprostane excretion extreme groups: associated
raits. The Online Table 1 and Online Figure 1 dichoto-
ize the twins/siblings above and below the urinary iso-
rostane median value of approximately 22.9 pg/mmol
normalized to creatinine). Individuals with higher urinary
soprostane excretion displayed a number of significant trait
ifferences, both biochemical (chromogranin, catechol-
mine, inflammatory) and physiological (body mass index,
nsulin resistance, cardiac, autonomic, and renal). Once
gain, several of the isoprostane-associated traits are com-
onents of the metabolic syndrome.
leiotropy (shared h2): genetic covariance with isopros-
ane excretion. We tested several heritable traits that
orrelated with urinary isoprostane excretion for shared
enetic determination (pleiotropy) with urinary isoprostane
xcretion (Table 1, Fig. 2). The results indicate that urinary
soprostane excretion shares significant genetic determina-
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Isoprostane and Heredity October 12, 2010:1338–50ion (pleiotropy, G) with body mass index, HOMA,
atecholamines, CHGB, leptin, baroreceptor coupling, and
xidized phospholipids. For CHGB, G with isoprostane
as 0.27  0.10 (p  0.007). By contrast, several correlated
raits also shared significant environmental determination
soprostane Excretion: Heritability and Shared Genetic and EnvironmeTable 1 Isoprostane Excretion: Heritability and Shared Genetic an
Nonparametric Trait-on-Trait
Correlation
Spearman  Sig. (2-tailed) h2
Demographic
Body mass index, kg/m2 0.015 0.746 0.86
Physiological/hemodynamic
Systolic blood pressure, mm Hg 0.023 0.619 0.47
Diastolic blood pressure, mm Hg 0.026 0.578 0.50
Heart rate, beats/min 0.121 0.009* 0.30
Biochemical: catecholamines
Epinephrine in urine, ng/g 0.129 0.008* 0.72
Norepinephrine in urine, ng/g (log[10]) 0.183 0.0001* 0.90
CHGB 439–451, nmol/l 0.130 0.004* 0.56
CHGB 568-577, nmol/l 0.100 0.084 0.58
Biochemical: metabolic
Plasma C-reactive protein, ug/l 0.140 0.002* 0.60
Plasma leptin, ng/ml 0.200 0.0001* 0.73
Plasma glucose, mg/dl 0.014 0.766 0.32
Plasma insulin, U/ml 0.137 0.003* 0.47
QUICKI 0.123 0.013* 0.42
HOMA 0.121 0.014* 0.54
Renal traits
GFR (MDRD), ml/min/1.73 m2 0.125 0.008* 0.70
Autonomic traits
Baroreceptor coupling at high freq
(0.15–0.4 Hz), ms/mm Hg
0.073 0.106 0.51
Baroreceptor coupling at low freq
(0.05–0.15 Hz), ms/mm Hg
0.089 0.049* 0.30
Baroreceptor coupling at very low freq
(0.01–0.05 Hz), ms/mm Hg
0.055 0.225 0.24
Baroreceptor upward slope, ms/mm Hg 0.087 0.054 1.00
Baroreceptor downward slope, ms/mm Hg 0.105 0.020* 0.38
Hemodynamic traits
Cardiac index, l/min/m2 0.134 0.004* 0.40
Stroke volume index, ml/m2 0.048 0.301 0.73
Systemic vascular compliance, ml/mm Hg 0.078 0.093 0.70
Brachial arterial compliance, ml/mm Hg 0.206 0.001* 0.64
Brachial arterial distensibility, %/mm Hg 0.158 0.001* 0.59
Lipids
Total cholesterol, mg/dl 0.049 0.402 0.40
LDL cholesterol, mg/dl 0.040 0.498 0.64
HDL cholesterol, mg/dl 0.027 0.640 0.68
Triglycerides, mg/dl 0.044 0.457 0.26
ApoA, mg/dl 0.069 0.237 0.62
ApoB, mg/dl 0.013 0.829 0.47
OxPL/ApoB (EO6), ratio 0.091 0.122 0.90
henotype correlations with isoprostane: Spearman (nonparametric) correlations were performed,
eritability (h2) (h2  VG/VP) of phenotypes in twins. Values of h
2 are mean  SEM, as the percen
ge- and sex-adjusted in Sequential Oligogenic Linkage Analysis Routines (SOLAR). The p valu
environmental covariance, E) determination for traits correlated with isoprostane. The G and E
ffects (p  0.05).
Apo  apolipoprotein; CHGB  chromogranin B; GFR  glomerular filtration rate; HDL  hig
ipoprotein; MDRD  Modification of Diet in Renal Disease; OxPL  oxidized phospholipids; QUICKenvironmental covariance, E) with isoprostane: HOMA, cxidized phospholipids, and arterial distensibility. Two
raits displayed both G and E with isoprostane: HOMA
nd oxidized phospholipids.
Figure 2 illustrates the substantial shared hereditary
etermination (G), without significant environmental
etermination With Associated Traits in Twin Pairsiron ental Determination With Associated Traits in Twin Pairs
h2
Shared Genetic Determination
(Pleiotropy)
Shared Environmental
Determination
p Value n G SEM p Value E SEM p Value
0.0001* 380 0.20* 0.08* 0.013* 0.09 0.09 0.298
0.0001* 380 0.03 0.17 0.760 0.05 0.08 0.481
0.0001* 380 0.01 0.10 0.952 0.08 0.08 0.357
0.0001* 380 0.06 0.13 0.638 0.01 0.08 0.890
0.0001* 380 0.09 0.09 0.528 0.12 0.09 0.322
0.0001* 380 0.34* 0.09* 0.001* 0.08 0.09 0.365
0.0001* 380 0.17 0.28 0.542 0.04 0.08 0.639
0.0001* 380 0.27* 0.10* 0.007* 0.13 0.09 0.173
0.0001* 380 0.20 0.10 0.067 0.09 0.11 0.440
0.0001* 380 0.27* 0.08* 0.002* 0.08 0.09 0.370
0.0001* 380 0.11 0.12 0.893 0.01 0.08 0.893
0.0001* 380 0.18 0.11 0.108 0.14 0.09 0.130
0.0001* 380 0.10 0.11 0.376 0.01 0.08 0.865
0.001* 380 0.42* 0.22* 0.029* 0.39* 0.08* 0.0001*
0.0001* 380 0.14 0.40 0.718 0.06 0.09 0.522
0.0001* 380 0.16 0.23 0.466 0.03 0.09 0.735
0.0094* 380 0.14 0.15 0.322 0.01 0.10 0.918
0.0018* 380 0.56* 0.30* 0.006* 0.13 0.09 0.160
0.0001* 380 0.03 0.08 0.687 0.05 0.09 0.578
0.0001* 380 0.14 0.14 0.300 0.12 0.09 0.169
0.0001* 380 0.08 0.09 0.395 0.11 0.09 0.228
0.0001* 380 0.11 0.09 0.255 0.11 0.09 0.193
0.0001* 380 0.04 0.10 0.652 0.16 0.09 0.300
0.0001* 380 0.10 0.16 0.514 0.05 0.08 0.528
0.0001* 380 0.004 0.12 0.97 0.19* 0.09* 0.030*
0.0001* 380 0.07 0.12 0.554 0.13 0.09 0.144
0.0001* 380 0.08 0.10 0.423 0.08 0.09 0.366
0.0001* 380 0.05 0.09 0.573 0.06 0.09 0.483
0.0067* 380 0.01 0.12 0.938 0.10 0.11 0.313
0.0001* 380 0.01 0.10 0.949 0.11 0.09 0.206
0.0001* 380 0.13 0.11 0.266 0.11 0.08 0.216
0.0001* 380 0.22* 0.08* 0.006* 0.21 0.08 0.017*
sibling from each twin pair (n  194 observations). Negative values indicate inverse correlations.
phenotypic variation (VP) explained by additive genetic factors (VG), in 190 twin pairs. Values are
e significance of the h2 estimate. Shared genetic (genetic covariance, G) and environmental
termined in SOLAR. Isoprostane excretion trait h2: h2  65.8 4.3%, p  5.48E-22. *Significant
ty lipoprotein; HOMA  HOmeostatic Model Assessment, insulin resistance; LDL  low-density
antitative Insulin sensitivity ChecK Index.ntal Dd Env
SEM
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nd CHGB.
ypertension and isoprostane excretion. Online Figure 1
tratifies 519 subjects by isoprostane quantile and BP status:
ypertensive (n  56) versus normotensive (n  463). We
bserved that subjects with elevated isoprostane excretion were
ver-represented in the hypertension group (p  0.0126).
he CHGB gene: pleiotropic genetic associations with
HGB secretion and isoprostane excretion. Because iso-
rostane excretion associated (Online Table 1) and aggre-
ated (Online Fig. 1) with CHGB expression and shared
enetic determination with CHGB (Fig. 2), we tested
hether genetic variation at the CHGB locus might also
nfluence the isoprostane trait. To visualize patterns of SNP
ssociations, we constructed pair-wise LD maps from 3
ommon SNPs (minor allele frequencies 5%) in the
egulatory regions (promoter or 3=-UTR) of CHGB. Two
locks of LD were noted by Haploview (49) (Fig. 3). The
ost common haplotype spanning the locus (haplotype-1:
TC) associated with isoprostane in twins: carriers of
aplotype-1 (1 or 2 copies; n  196), as compared with
ubjects without haplotype-1 (0 copies; n  137), displayed
educed isoprostane excretion (28.7  1.79 pg/mmol vs.
Figure 1 Heritability of Isoprostane Excretion, Biochemical, Re
Studies in twin pairs. Plasma CHGB439–451 (nmol/l), urinary epinephrine (ng/g), u
HOmeostatic Model Assessment (HOMA) (insulin resistance), baroreceptor slope (ms5.0  1.17 pg/mmol, chi-square  5.24, p  0.022). pBecause 3=-UTR SNP C84A seemed to reside in a
lock of relatively low LD with the promoter region (r2 
.19 to 0.20) (Fig. 3), we tested the effect of the 3=-UTR
ariant separately (Table 2); A allele homozygosity (A/A)
levated plasma CHGB (p  0.0123) as well as isoprostane
xcretion (p 0.0111). For the 2 promoter SNPs (A-296C,
-261T), no associations with isoprostane excretion were
ound (Table 2).
HGB 3=-UTR variant function in cella. To test whether
he CHGB 3=-UTR C84A variant is itself functional, we
nserted the 308-bp 3=-UTR into a reporter plasmid just
ownstream from the luciferase open reading frame and
erived the minor allele version (84A) by site-directed
utagenesis (Fig. 4A). Luciferase activities of C84,
84A, and the “empty” vector were measured sequentially
fter transfection into chromaffin/PC12 cells (Fig. 4B). The
84 allele displayed gain-of-function as compared with
he empty vector, whereas the 84A variant had loss-of-
unction. By 36 h, the A allele destabilized expression by
pproximately 47% compared with the C allele (p 0.001).
esults of transfection of CHGB 3=-UTRs into human
euroblastoma (SH-SY5Y) cells were similar to those in rat
nd Autonomic Traits
soprostane (pg/mmol creatinine), plasma C reactive protein (ug/l),
g), cardiac index (l/min/m2), and glomerular filtration rate (ml/min/1.73 m2).nal, a
rinary i
/mm Hheochromocytoma (PC12) cells.
C
p
s
(
(
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Isoprostane and Heredity October 12, 2010:1338–50HGB 3=-UTR site-directed mutants: function in cella. To
ursue the mechanism of action of C84A, we created a
eries of mutants in the luciferase/3=-UTR plasmid
Figure 2 Genetic (RhoG) and Environmental (RhoE) Covariance
Results are shown as the mean  SEM for the estimates in twin pairs, plotting Rh
is the theoretical line of identity (y  x). Significance of RhoG or RhoE estimates i
Figure 3 Patterns of LD at the Human CHGB Locus (Regulatory
The linkage disequilibrium (LD) map across the approximately 14.0 kilobase pair (
try) individuals (2n  376 chromosomes). The “solid spline” method was used to
defined by solid spline rule; r2 color scheme: r2  0, white; 0  r2  1, shades o
was assigned to a different LD “block” by the solid spline method, on the basis o
phisms (SNPs) at CHGB. CHGB  chromogranin B.Fig. 4A), followed by transfection into PC12 cells
Fig. 4C). Compared with the wild-type (C84) allele,
uciferase reporter activity fell by approximately 21% (p 
Traits Correlated With Urinary Isoprostane
a function of RhoE. The diagonal line
n by the p values. CHGB  chromogranin B.
ants: Promoter and 3=-UTR)
cus was constructed by Haploview, with 188 unrelated white (European ances-
n haplotype block boundaries. Numbers in diamonds: LD as r2*100; LD blocks
; r2  1: black. CHGB 3=-UTR variant C13612A (C84A in the 3=-UTR; rs2821)
vely low r2 (  0.19-0.20) LD with the promoter region single nucleotide polymor-s for
oG as
s showVari
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October 12, 2010:1338–50 Isoprostane and Heredity.001) when the entire A/U-rich element was deleted.
anipulation of the wild-type C84 allele, through either
eletion of 1 base or replacement by the 84A variant,
esulted in more substantial (approximately 31% to 41%)
alls in gene expression. The results suggest that the A/U-
ich region regulates CHGB expression and that C84A
erves as a crucial switch within this element.
HGB 3=-UTR C84A within an A/U-rich messenger
ibonucleic acid element: bioinformatics. We aligned
84A and its flanking sequences in humans and other
ammalian species by Clustal-W. The C84A lies in a
ubstantially conserved region of the messenger ribonucleic
cid (mRNA) (Fig. 5). The C84 (human major) allele is
ound in nonhuman primates (chimp, Rhesus), whereas
onprimate mammals have a T allele at this position. Only
he human has the 84A variant, extending an A/U
A/T)-rich region (TTTATATA; position 84 in bold
ype) suggesting a motif that could affect the mRNA
tability and hence overall gene expression (51); a decline in
xpression with extension of this element is consistent with
ts role in mRNA instability. Such A/U-rich elements (or
ARE”s) might be targets of trans-acting factors that
ediate mRNA instability, such as the Hu family of
roteins (52,53).
iscussion
verview. The current study demonstrates that isopros-
ane excretion is substantially heritable (h2  65.8  4.3%,
 5.48E-22) and both correlated (Online Table 1) and
ggregated (Online Fig. 1) with several components of the
etabolic syndrome; indeed, isoprostane displays substan-
ial genetic co-determination with several such traits
Fig. 2), and the isoprostane trait is associated with systemic
ypertension (Fig. 6).
Because CHGB and isoprostane shared h2 (G) (Fig. 2),
e tested the CHGB locus for the effects of allelic variation
n CHGB and isoprostane traits and found that common
unctional variation in the CHGB 3=-UTR associated with
oth traits (Table 2). The results suggest novel functional
inks among adrenergic pathways, oxidative stress, and
ypertension. An unusual feature of this study was the use
ssociations Among CHGB Genetic Variants, Isoprostane ExcretionTable 2 Associations Among CHGB Genetic Variants, Isoprosta
CHGB Regulatory SNP Genotype n
Isopros
Mean 
Promoter A-296C (rs236140) A/A 112 1.39
A/C or C/C 187 1.45
Promoter A-261T (rs236141) A/A 112 1.39
A/T or T/T 187 1.34
3=-UTR C84A (C13612A in gene, rs2821) C/C or C/A 273 1.34
A/A 61 1.44
y generalized estimating equations; age-, sex- and glomerular filtration rate (GFR)-adjusted. *Sig
CHGB  chromogranin B; SNP  single nucleotide polymorphism.f the twin method, to dissect out complex features of the sode of inheritance of isoprostane, including h2 and pleiot-
opy (Figs. 1 and 2).
ole of catecholamines and isoprostanes in hypertension.
atecholamines are known to trigger oxidative stress
hrough adrenergic receptors in cardiovascular and renal
arget cells, thereby activating NADPH oxidase isoforms
54–56). Genetic variation at the CHGB locus alters cate-
holamine secretion in both humans and experimental
nimals (30,32). We have previously demonstrated evidence
f increased oxidative stress in human hypertension, as
ndicated by elevated hydrogen peroxidase generation (8,9).
The 8-iso-PGF2 not only is a marker of oxidative stress
ut also participates in the pathophysiology of disease
hrough its direct vasoconstrictive effects, as evidenced in
he pulmonary artery (57), coronary arteries (58), cerebral
rterioles (59), and portal vein (60). Elevated 8-iso-PGF2
evels have previously been associated with longitudinal risk
f developing hypertension (21).
Urinary excretion of isoprostane correlated positively with
lomerular filtration rate (  0.125, p  0.008) (Table 1).
lthough we did not measure the plasma concentration of
soprostane, urine and plasma values generally correlate well
61); however, there are occasional discrepancies (62).
omplex inheritance of isoprostane: pleiotropy. The
win design allowed us to explore pleiotropy (shared genetic
etermination of 2 or more traits), documented as the
enetic covariance (G) (Table 1 and Fig. 2) between
orrelated traits. Of the many traits correlated or associated
ith isoprostane excretion, pleiotropy was noted for cate-
holamine secretion, CHGB, leptin, baroreceptor coupling,
polipoprotein A, and oxidized phospholipids. What spe-
ific genes might jointly contribute to such traits? We
xplored the role of genetic variation at the CHGB locus,
ecause CHGB and isoprostane shared G (Fig. 2), yet
olymorphisms at other genes not directly scored in this
eport could jointly contribute to multiple facets of the
etabolic syndrome.
unctional nature of polymorphism at CHGB. The
HGB is abundant within catecholamine secretory ves-
cles and might be necessary for inducing secretory
ranule formation (29). The twin data indicate that the
oncentrations of CHGB circulating fragments are under
Plasma CHGBxcretion, and Plasma CHGB
xcretion, pg/mmol (log[10]) Plasma CHGB439–451, nmol/l
Chi-Square p Value Mean  SEM Chi-Square p Value
1.93 0.1651 0.32 0.02 7.46 0.0063*
0.39 0.01
2.31 0.1283 0.33 0.02 7.16 0.0074*
0.38 0.01
6.45 0.0111* 0.37 0.01 6.22 0.0123*
0.32 0.01
t effects (p  0.05)., andne E
tane E
SEM
0.02
0.03
0.02
0.02
0.02
0.02ubstantial genetic control (Table 1), suggesting that
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Isoprostane and Heredity October 12, 2010:1338–50Figure 4 Functional Evaluation of Common Allelic Variation in the CHGB 3=-UTR: C84A (C13612A)
(A) Human CHGB 3=-UTR reporter plasmid construction. The 308-bp CHGB 3=-UTR fragment was amplified from human genomic deoxyribonucleic acid and (pGL3-Pro-
moter, with the SV40 early promoter) (Promega, Madison, Wisconsin), just 3= to the luciferase open reading frame (ORF) but upstream from the polyadenylation (pA) sig-
nal. Correct insert orientation was confirmed by asymmetric double digestion with restriction enzyme MfeI, which cuts once within the insert, and nearby in the vector at
position 2103, within the SV40 pA cassette. Variants were created by site-directed mutagenesis (QuikChange; Stratagene, La Jolla, California), and mutations were veri-
fied by direct sequencing before use. Point mutations were confirmed by dideoxy sequencing. (B) CHGB common 3=-UTR C84A polymorphism affects transfected gene
expression. When transfected into chromaffin (rat pheochromocytoma, PC12) cells, 3=-UTR variant C84A influenced luciferase reporter gene expression in vitro, in a
direction (CA) coordinate with the in vivo effects. Compared with the empty pGL3-Promoter vector alone, the C84 exhibits a gain of function, whereas 84A has a
loss of function. At 36 h, the A allele destabilized expression by approximately 47% (compared with the C allele). (C) CHGB 3=-UTR: function of A/U (A/T)-rich region in
the luciferase reporter in transected chromaffin (PC12) cells. Several mutations were created in the A/U-rich region. Removal of the entire A/U-rich region resulted in an
approximately 21% fall in gene expression. Manipulation of the wild-type C84 allele, through either deletion of 1 base or replacement by the 84A variant, resulted in
more substantial (approximately 31% to 41%) declines in gene expression. ANOVA  analysis of variance; CHGB  chromogranin B.
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October 12, 2010:1338–50 Isoprostane and Heredityirculating CHGB might be a useful “intermediate phe-
otype” (63) in the pathogenesis of hypertension. The
HGB has both extracellular and intracellular roles in
he neuroendocrine system (64), and its deficiency is
ssociated with dysregulated catecholamine secretion and
ypertension (32).
Several findings in this study suggested that polymor-
hism in the 3=-UTR of CHGB might be functionally
mportant for inter-individual variation in autonomic as
ell as oxidative traits. First of all, the 3=-UTR region
ssociated with plasma CHGB concentration as well
soprostane excretion (Table 2). Second, 3=-UTR com-
on polymorphism C84A influenced gene expression
n cella (Fig. 4B), perhaps by altering an A/U-rich
tability motif in a conserved sequence within the mRNA
Fig. 4C). Third, the changes conferred by allelic varia-
ion at C84A seemed to be directionally consistent: the
84 (major) allele elevated gene expression both in
ella (Fig. 4B) and in vivo (Fig. 7). Finally, because the
=-UTR region of CHGB displays only minimal LD with
he remainder of the CHGB locus (Fig. 3), it is perhaps
ot surprising that the 3=-UTR might exert a relatively
ndependent contribution to the regulation of CHGB
xpression.
onclusions and Perspectives
soprostane excretion is a highly heritable trait, display-
ng joint genetic determination (pleiotropy) with such
raits as CHGB, catecholamines, leptin, baroreceptor
ment and conservaon (by Clustal W)    - .
h
TACCCAAGGGCAGAAAGTAGAACTTA
TACCCAAGGGCAGAAAGTAGAACTTA
TACCCAAGGGCAGAAAGTAGAACTTA
TATCCAAGGACAGAAAGTAGAACTTA
TACCCAAAGGCAGAAAGTAGAATTTA
TATCCAAAGGCAGAAAGTAGAATTTA
TACCCAAAAGCAGAAAGTAGAATTTA
CACCCAAAGGCAGAAAGCAGAATTTA
CACCCACAGGCAGAAAGCAGAATTTA
 * ***    ******* **** ***
4A
12A)
4A lies in a conserved 3=-UTR local region of the CHGB messenger ribonucleic
ammals have the T allele at this position. The C84A occurs in an A/U (A/T)-rich
) or from public databases (National Center for Biotechnology Information).Mammalian inter species sequence align -   
A/T-ric
Human variant   AAGACACCATTTATA
Human ref seq   AAGACACCATTTATC
Chimp           AAGACACCATTTATC
Rhesus AAGACACCATTTATC          
Pig             AAGACACCATTTATT
Cow             AAGACCCCATTTATT
Dog             AAGACACCATTTATT
Rat             AAGACAGCATTGATT
Mouse           AGGACACCATTGATT
Conservation    * ***  **** ** 
C+8
(C136
Italics: A/T (A/U) -rich element
B ld P i f C 84Ao : os on o  +
Figure 5 Human CHGB 3=-UTR Common Variant C84A
Mammalian inter-species sequence alignment and conservation (by Clustal-W). The C8
acid. The C84 (human major) allele is found in other primates, whereas nonprimate m
(stability) element in the message. Sequences were obtained by re-sequencing (primates
CHGB  chromogranin B.Figure 6 Renal Isoprostane Excretion and BP
Isoprostane excretion (normalized to creatinine), stratified into upper and lower
quantiles: effect on blood pressure (BP) status in twin and sibling pairs (chi-
square  6.22, p  0.0126 by generalized estimating equation [GEE]; age-
and sex-adjusted).oupling, lipids, and oxidized phospholipids. On the
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Isoprostane and Heredity October 12, 2010:1338–50asis of pleiotropic genetic control of isoprostane and
HGB (Fig. 2), we tested the role of CHGB genetic
ariation and found that a common polymorphism in the
HGB 3=-UTR that alters an A/U-rich mRNA stability
lement (Fig. 4C) contributes to trait variation in CHGB
nd isoprostane (Table 2). Therefore we propose the
ollowing model to unify our results in a parsimonious
ashion: CHGB 3=-UTR C84A variation (C¡A at
osition 84) destabilizes CHGB mRNA, leading to
ecreased CHGB expression, prompting unregulated
atecholamine release (32), thereby triggering oxidative
tress (54,55). The twin method used here initially
ocused on healthy individuals rather than subjects with
vert cardiovascular disease; only longitudinal/follow-up
tudies can establish the ultimate risk conferred by CHGB
enotype or elevated isoprostane in these subjects. How-
ver, our results suggest novel pathophysiological links
etween the CHGB gene and oxidative stress, inflamma-
ion, and hypertension and suggest new strategies for
robing the role and actions of oxidative stress within this
etting.
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Figure 7 Common Genetic Variation in the Human CHGB 3=-UT
Differential Effects on Transfected Reporter Expressio
Pleiotropic effects on gene expression in cella, and human chromogranin B (CHGB
cells and plasma CHGB in vivo. Plasma CHGB439–451 as a function of luciferase r
gosity was estimated by a 1:1 mix of the C or A allele plasmids. ANOVA  analysi-mail: doconnor@ucsd.edu.EFERENCES
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